GlassScriptPhysician profile
Daniel B Mcginley
NPI 1598926248
$11,636.94
in general payments reported to CMS, 2019-2025
53 companies · $2,283 in 2025
The $2,283 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $778 · 2021: $1,275 · 2022: $1,604 · 2023: $1,983 · 2024: $2,188 · 2025: $2,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,399 · Education: $55.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,399.09 |
| Education | $55.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,393.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,260.78 | 2019-2025 | |
| Lilly USA, LLC | $1,018.65 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $982.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $933.33 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $571.79 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.95 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $495.43 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $438.54 | 2019-2025 | Steglatro, Belsomra, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $364.86 | 2019-2022 | |
| Abbott Laboratories | $340.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $315.10 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $225.50 | 2021-2024 | |
| Exact Sciences Corporation | $224.47 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $151.22 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcginley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.